Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

Kazuhiko Kurozumi; Kentaro Fujii; Kana Washio; Joji Ishida; Yoshihiro Otani; Tamotsu Sudo; Makoto Tahara; Koichi Ichimura; Daisuke Ennishi; Isao Date

doi:10.1093/noajnl/vdac094

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

Kazuhiko Kurozumi, Kentaro Fujii, Kana Washio, Joji Ishida, Yoshihiro Otani, Tamotsu Sudo, Makoto Tahara, Koichi Ichimura, Daisuke Ennishi, Isao Date

University Hospital

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.

Original language	English
Article number	vdac094
Journal	Neuro-Oncology Advances
Volume	4
Issue number	1
DOIs	https://doi.org/10.1093/noajnl/vdac094
Publication status	Published - Jan 1 2022

ASJC Scopus subject areas

Clinical Neurology
Oncology
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/noajnl/vdac094

Cite this

@article{6200625225824360ac403f499f10bfee,

title = "Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion",

abstract = "Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.",

author = "Kazuhiko Kurozumi and Kentaro Fujii and Kana Washio and Joji Ishida and Yoshihiro Otani and Tamotsu Sudo and Makoto Tahara and Koichi Ichimura and Daisuke Ennishi and Isao Date",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1093/noajnl/vdac094",

language = "English",

volume = "4",

journal = "Neuro-Oncology Advances",

issn = "2632-2498",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

AU - Kurozumi, Kazuhiko

AU - Fujii, Kentaro

AU - Washio, Kana

AU - Ishida, Joji

AU - Otani, Yoshihiro

AU - Sudo, Tamotsu

AU - Tahara, Makoto

AU - Ichimura, Koichi

AU - Ennishi, Daisuke

AU - Date, Isao

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.

AB - Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85134933963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134933963&partnerID=8YFLogxK

U2 - 10.1093/noajnl/vdac094

DO - 10.1093/noajnl/vdac094

M3 - Article

AN - SCOPUS:85134933963

SN - 2632-2498

VL - 4

JO - Neuro-Oncology Advances

JF - Neuro-Oncology Advances

IS - 1

M1 - vdac094

ER -

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this